Related Experiment Videos
A small sample confidence interval approach to assess individual bioequivalence
T Hyslop1, F Hsuan, D J Holder
1Biostatistics Section, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, 132 S. 10th Street, 1170 Main Building, Philadelphia, PA 19107-5244, USA. terry.hyslop@mail.tju.edu
Statistics in Medicine
|October 18, 2000
Summary
This study introduces a computationally efficient method for assessing individual bioequivalence (IBE) in pharmaceutical products. The new approach supports regulatory criteria for interchangeable drugs, offering a practical alternative to intensive bootstrap methods.
Area of Science:
- Pharmaceutical Sciences
- Biostatistics
- Pharmacokinetics
Background:
- The interchangeability of pharmaceutical products is crucial for drug efficacy and patient safety.
- Individual bioequivalence (IBE) and population bioequivalence (PBE) are key concepts for assessing drug product equivalence.
- Current FDA draft guidance recommends IBE and PBE using computationally intensive non-parametric bootstrap methods.
Purpose of the Study:
- To develop an alternative, computationally efficient confidence interval procedure for assessing individual bioequivalence (IBE).
- To provide a method applicable to regulatory criteria for interchangeable pharmaceutical products.
- To offer a practical solution for evaluating IBE in various study designs.
Main Methods:
- Utilized Howe's approximation I to a Cornish-Fisher expansion for confidence interval calculation.
- Developed an alternative procedure to the non-parametric bootstrap method.
- The method is designed for balanced or unbalanced data in extended cross-over designs.
Main Results:
- The proposed method provides a computationally feasible alternative for assessing IBE.
- The procedure aligns with FDA-recommended criteria for individual bioequivalence.
- The method is adaptable for programming in standard statistical software.
Conclusions:
- A novel, efficient statistical method for assessing individual bioequivalence has been developed.
- This approach simplifies the computational demands associated with current bioequivalence assessment methods.
- The proposed procedure offers a practical tool for pharmaceutical regulatory science and drug development.